[HTML][HTML] Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
GH Xia, Y Zeng, Y Fang, SR Yu, L Wang… - Cancer Biology & …, 2014 - ncbi.nlm.nih.gov
Objective Non-small cell lung cancer (NSCLC) patients with epidermal growth factor
receptor (EGFR)-activating mutations have higher response rate and more prolonged …
receptor (EGFR)-activating mutations have higher response rate and more prolonged …
Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer–A multicenter retrospective SEQUENCE …
GC Chang, CH Tseng, KH Hsu, CJ Yu, CT Yang… - Lung Cancer, 2017 - Elsevier
Background Acquired resistance occurs in most non-small cell lung cancer (NSCLC)
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
patients with epidermal growth factor receptor (EGFR) mutations experiencing a response to …
Subsequent treatment of epidermal growth factor receptor‐tyrosine kinase inhibitor failure in patients with advanced lung adenocarcinoma
X Qiao, Y Zhang, J Wang, J Nong, X Li, X Yang… - Thoracic …, 2015 - Wiley Online Library
Background Epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs)
effectively treat advanced non‐small cell lung cancer with EGFR‐mutation. However, most …
effectively treat advanced non‐small cell lung cancer with EGFR‐mutation. However, most …
Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy
S Kanda, H Horinouchi, Y Fujiwara, H Nokihara… - Lung Cancer, 2015 - Elsevier
Objectives In the first-line treatment of non-small cell lung cancer (NSCLC) harboring EGFR
mutations, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has …
mutations, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has …
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?
JY Lee, SH Lim, M Kim, S Kim, HA Jung… - Cancer chemotherapy …, 2014 - Springer
Abstract Background Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
receptor (EGFR) have demonstrated some dramatic response rate and prolonged …
Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer.
J Li, L Qu, X Wei, H Gao, W Wang… - Chinese Journal of …, 2012 - search.ebscohost.com
Abstract Abstract Background and objective It has been proven that epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) significantly benefits advanced non-small cell …
receptor-tyrosine kinase inhibitor (EGFR-TKI) significantly benefits advanced non-small cell …
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer …
Y Kato, K Hotta, N Takigawa, N Nogami… - Cancer chemotherapy …, 2014 - Springer
Purpose Early administration of both epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) monotherapy and cytotoxic chemotherapy is crucial for non-small cell …
inhibitor (EGFR-TKI) monotherapy and cytotoxic chemotherapy is crucial for non-small cell …
Clinical Impact of Switching to a Second EGFR-TKI After a Severe AE Related to a First EGFR-TKI in EGFR-mutated NSCLC
M Takeda, I Okamoto, J Tsurutani, N Oiso… - Japanese journal of …, 2012 - academic.oup.com
Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …
[HTML][HTML] Strategies to improve outcomes of patients with EGFR-mutant non–small cell lung cancer: review of the literature
C Zhou, L Di Yao - Journal of Thoracic Oncology, 2016 - Elsevier
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations
K Uchibori, M Satouchi, N Sueoka-Aragane, Y Urata… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (ie, EGFR-
TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the …
TKIs) improve the survival of lung cancer patients harboring EGFR mutations. Despite the …
Related searches
- egfr tkis acquired resistance
- egfr tkis cytotoxic chemotherapy
- egfr tkis genetic alterations
- clinical impact egfr tki
- egfr tyrosine lung cancer
- kinase inhibitor lung cancer
- egfr tyrosine kinase inhibitor
- growth factor receptor tyrosine
- predictive factors lung cancer
- acquired resistance cytotoxic chemotherapy
- egfr tyrosine predictive factors
- growth factor lung adenocarcinoma
- kinase inhibitor predictive factors
- egfr tkis primary resistance
- clinical observation egfr tki
- egfr tkis clinical outcome